The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial [Research Watch]

Tazemetostat has antitumor activity in B-cell non-Hodgkin lymphoma and advanced solid tumors.

from Cancer via ola Kala on Inoreader https://ift.tt/2HgegDj
via IFTTT